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This  paper  reports  on  some  of  the  key  outcomes  of  a 3  year  £1.5 m  Technology  Strategy  Board  (TSB)
funded  research  programme  to  develop  a small  footprint,  versatile,  counter-current  chromatography
puriﬁcation  technology  and  methodology  which  can  be  operated  at a  range  of  scales  in both  batch and
continuous  modes  and  that  can  be  inserted  into  existing  process  plant  and  systems.  Our  consortium,  inte-
grates  technology  providers  (Dynamic  Extractions)  and  the  scientiﬁc  development  team  (Brunel)  with
end user  needs  (GSK  &  Pﬁzer),  addressing  major  production  challenges  aimed  at providing  ﬂexible,  low
capital platform  technology  driving  substantial  cost  efﬁciency  in  both  drug  development  and  drug  man-
ufacturing  processes.  The  aims  of  the  Technology  Strategy  Board’s  high  value  manufacturing  programme
are  described  and  how  the  academic/industry  community  were  challenged  to  instigate  step  changes  in
the  manufacturing  of  high  value  pharmaceuticals.  This  paper  focusses  on  one  of  the  themes  of  the  TSB
research  programme,  “Generate  a Comprehensive  Applications  Portfolio”.  It  outlines  15 applications  from
this  portfolio  that  can  be  published  in  the  public  domain  and  gives  four  detailed  case  studies  illustrat-
ing  the  range  of  application  of  the  technology  on  the  separation  of  (1)  isomers,  (2)  polar  compounds,
(3)  crude  mixtures  and  (4)  on the  removal  of  impurities.  Two  of  these  case  studies  that were  scaled  up
demonstrate  between  10 and  20%  lower  solvent  usage  and  were  projected  to  have  signiﬁcant  cost  savings
compared  to conventional  solid  phase  silica gel  chromatography  at procss  scale  demonstrating  that  the
latest  high  performance  countercurrent  chromatography  technology  is  a competitive  platform  technolgy
for the  pharmaceutical  industry.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction
This paper highlights the major outputs from a 3 year Technol-
gy Strategy Board high value manufacturing research programme
anaged by end users from the pharmaceutical industry (GSK
nd Pﬁzer), technologically driven by a supply company (Dynamic
xtractions Ltd.) with research support from academia (Brunel
niversity). The research programme aims to drive substantial
ost efﬁciency in both drug development and drug manufacturing
rocesses by developing commercial counter-current separation
 Presented at the 7th International Conference on Countercurrent Chromatogra-
hy,  Hangzhou, China, 6–8 August 2012.
∗ Corresponding author at: Brunel Institute for Bioengineering, Brunel University,
xbridge, Middlesex UB8 3PH, UK. Tel.: +44 01895 266920; fax: +44 1895 274608.
E-mail address: ian.sutherland@brunel.ac.uk (I. Sutherland).
021-9673     ©  2013 Elsevier B.V. 
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Open access under CC BY-NC-ND license.technology to the point where it will allow selective puriﬁcations to
be achieved at loadings of approximately 1 kg/day at the laboratory
scale.
In contrast to high-performance liquid chromatography,
counter current separations [1–5] do not require expensive pack-
ing materials; are more tolerant of particulate matter and have the
beneﬁt of excellent reproducibility. The project will demonstrate
the broad applicability of the technology to pharmaceutical sepa-
ration problems and speciﬁc examples will more closely examine
the capability of the technology for increased sample loading and
scale-up.
This paper will not go into detail on how the technology works
as this has been described elsewhere [1–5], but this is a maturing
technology with developing supply companies that are continu-
ously improving the technology robustness so that it becomes the
platform technology the industry needs.
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. The aims of the TSB high value manufacturing
rogramme
The Technology Strategy Board’s high value manufacturing
esearch programme highlights that “manufacturing globally is a
ey provider of wealth and employment” and that “manufacturing
s also one of the primary mechanisms for realising wealth from
ew technologies and is therefore critical to the UK”. It also main-
ains that manufacturing is highly competitive and gravitates to
ountries of lowest overall cost. Therefore, manufacturing in com-
aratively high wage economies, such as the UK, has had to change
adically to remain globally competitive.
The TSB set up a “High Value Manufacturing” competition to
und “step changes in competitiveness” in January 2009 focussing
n innovation in four broad areas which they called the “four pillars
f high value manufacturing”: (1) products; (2) production pro-
esses; (3) service systems and (4) value systems planning to invest
n projects that will, over the duration of the project, bring about
ajor changes – STEP CHANGES – in the competitiveness of the
articipating companies.
This competition inspired us to set up our consortium of end-
sers, supply companies and academics to address the issues facing
he pharmaceutical industry. From a chemical development point
f view, the pharmaceutical industry was facing the following
ajor challenges: (1) to make signiﬁcant quantities of materials
or early phase testing very rapidly, with good purity and cost
ffectively and (2) to develop production processes that were both
obust and highly cost effective. We  proposed the introduction of
ew technology to the pharmaceutical industry that would cre-
te a much more ﬂexible, small footprint, integrated puriﬁcation
echnology which would be scalable, transferable, containable and
ore environmentally friendly. Being a TSB proposal, they were
nterested in the business opportunities addressed – i.e. not just in
evelopment but in manufacture as well. These were as follows:
a) rapid and cost-effective access (compared to existing technolo-
ies) to signiﬁcant amounts of drug substances for development
urposes resulting in large reductions in early development time-
ines and associated costs; (b) ease of technology transfer from
mall scale R&D stages (pre-clinical) to commercialisation; (c)
ortability of processes that can be validated in the UK and
ransferred anywhere globally without changing the process itself
ence maximising commercial beneﬁt and minimising the asso-
iated regulatory issues; (d) an environmentally friendly process
hich contains the product, that can be easily cleaned or disposed
f, and uses orders of magnitude less solvent than conventional
rocesses; (e) large scale, robust and cost-effective manufactur-
ng technology that will permit batch or continuous puriﬁcation,
roadening processing options and lowering overall production
osts.
We proposed a step-change in the manufacture of high value
harmaceuticals, which would be critical if UK companies wanted
o maintain global competitiveness in the face of the move of man-
facturing bases to low cost countries. We  proposed our liquid
ow technology as having applications in a variety of key areas:
1) with reductions in process development timelines and costs
y up to 50% by allowing rapid access to puriﬁed materials; (2)
llowing potentially signiﬁcant savings in manufacturing process
osts by offering simpliﬁed manufacturing processes with fewer
teps; increased yields as a result of the processing of liquors that
ould otherwise have been discarded; the removal of impurities
llowing potential access to less expensive starting materials/less
xpensive synthetic routes and the capability to input very high
uality materials into crystallisation processes potentially lower-
ng risks associated with solid state issues; (3) involvement of
quipment designers/manufacturers at every stage in develop-
ent would facilitate equipment design enhancements and (4)gr. A 1282 (2013) 84– 94 85
preparative chromatographic separations were growing at an
annual rate of greater than 20% (Strategic Directions Interna-
tional Inc.), which was of major interest to the Pharma industry.
A successful outcome to the project would globally stimulate
the market at all scales, leading to signiﬁcant increases and
growth in sales of the technology. Critically, the team felt that the
project would allow a substantial body of experience to be gained
with counter-current chromatography and associated equipment
allowing major advances to be made in equipment capability
and reliability. The end-users would become familiar with the
scope and ﬂexibility of using liquid processing streams and fur-
ther new ideas and innovative uses of the technology would
develop.
The TSB HVM competition was launched in January 2009. It
was  a two  stage process. Our expression of interest entitled “Scal-
able Technology for the Extraction of Pharmaceuticals (STEP)” was
ranked in the top ten of more than 300 entries and our ﬁnal pro-
posal was eventually funded in June 2009 with the project starting
on September 1st, 2009.
3. The TSB-STEP research programme
The initial proposal advocated 5 end user applications and pro-
posed a phased programme of development and validation at the
analytical scale in the ﬁrst year (Phase 1); laboratory scale in the
second year (Phase 2) and pilot/process scale in the third year
(Phase 3). As the project evolved it became clear that the end-
user companies required a much larger applications portfolio to
persuade senior management to invest more resource into the
project. The research programme, being end-user driven, evolved to
become theme driven where the themes were dictated by the needs
of the end-user industries in the consortium. These themes were (1)
instrument integration and automation; (2) generate a comprehen-
sive applications portfolio; (3) new solvent system development;
(4) improve instrument reliability; (5) continuous processing and
scale-up; (6) demonstrating value and (7) management – includ-
ing a dissemination and exploitation plan. Themes (1) and (4)
involving instrument development and Theme (6) demonstrating
value will be presented at SPICA 2012 in Brussels on October 2nd,
2012; Themes (2), (3) and (5) were presented at the CCC2012
conference in Hangzhou, China. Theme (2) will be reported in
this paper while Themes (3) and (5) will be in separate publica-
tions in either the SPICA or CCC2012 special editions respectively
[6,7].
4. Generating a comprehensive applications portfolio
In total more than 30 applications were processed as part of the
TSB research programme. Tables 1–4 list 15 of these that have been
approved for general release divided into isomeric compounds (1–5
– Table 1); highly polar compounds (6 and 7, Table 2); crude mix-
tures (8–12, Table 3) and removal of impurities (13–15, Table 4) –
the others are commercially sensitive. Of the 30 applications more
than 85% achieved their target separation. Of those listed in Tables
1–4, applications 1, 10, 13 and 14 were the case studies 1, 2, 3 and
4 presented at CCC2010 in Lyon, France and described in detail in
the ﬁrst TSB-STEP publication in the CCC2010 special issue of the
Journal of Chromatography A [8].  One application from each of the
groupings here has been selected for a detailed description. Case
Study 1: applications 2 from isomeric compounds in Table 1; Case
Study 2: application 7 from highly polar compounds in Table 2;
Case Study 3: application 9 from crude mixtures in Table 3 and
Case Study 4: application 15 from removal of impurities in Table 4.
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Table 1
Details of example applications involving isomeric compounds used for HPCCC assessment.
Example Mixture Loading Solvent system Result
1
H
NR2
R1 Me
H
R1 NR2
Me 10 mg  Hept:DCM:MeCN
[5:0.5:4.5]
Baseline
separation. Not
optimised. Non
aqueous system
required for
solubility
2 Z
Y
NO2
Z
Y
NO2
 Y and Z = C or N 
50 mg  HEMWat
SS11 + 0.1% HCl –
RP
Scaled to Spectrum
semi-prep column.
260 mg injection to
give 77% recovery
of product
containing <0.5% of
unwanted isomer
3
R
OH
R
OH
300 mg HEMWat SS19
[3:2:3:2] – NP
Product contains
<1% of unwanted
isomer
4
R1
R2
HN R3
O
OH
R1
R2
HN R3
O
OH
No separation No systems
identiﬁed
Range of solvent
systems
investigated
5 Z
Y
NH2
Z
Y
NH2
Y and Z = C or N 
15 mg DCM:MeOH:0.2%
aq. Formic
acid + Et3N – pH
3.5: Propan-2-ol
Sample had poor
solubility in most
organic solvents.
Product contains
5
5
5
t
T
D. Application case studies
.1. Case Study 1: separation of isomers.1.1. Separation
The crude sample (application 2, Table 1) contains a mixture of
wo isomers, about 60% of the required isomer (ratio of required
able 2
etails of example applications involving polar compounds used for HPCCC assessment.
Example Mixture 
6
O
OH
HO
HO
N
H
ArNH2
Ar O
OH
HO
HO
N
H
Parent                         Impurity A 12%                 Impu rit y B 30%
7
R1 N O
P
O O
O
O
R2
Na
+
Na
+
+ Unkno wn  impu rit ies at 0.8% and 1. 5%[6:2:4:3] – NP <0.5% unwanted
isomer
to unwanted isomer is 1.8:1). The aim was to purify the required
isomer with less than 0.5% of the unwanted isomer. Any other
impurities were to be kept for further analysis.5.1.2. Solvent system selection
Initial scouting runs on a DE Mini (18 ml  column, 0.8 mm bore)
using an automated solvent mixing on demand system homed in
Loading Solvent system Result
Ar
20 mg MeCN:n-PrOH:21%
aq. (NH4)2SO4
[2.5:5:11] – NP
Impurity A isolated
in 90% purity
impurity B isolated
in 60% purity
27 mg  n-BuOH:MeCN:1M
aq NaOAc [4:1:5] –
NP
Unknown
impurities reduced
to <0.1%
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Table 3
Details of example applications involving crude mixtures used for HPCCC assessment.
Example Mixture Loading Solvent system Result
8
Ar
O
EtO
Ar
OOEt
Ar
OOH
+ two unkno wns
56 mg  Isocratic HEMWat  SS18
[6:5:6:5] then gradient
from SS18 to SS8
[1:9:1:9] then Isocratic
HEMWat SS8 – NP
Four components
obtained at >95%
purity, one
component 60%
purity
9
OH
R
OH
X
R
OH
X
MeO
R
X
MeO
OMe
55 mg  HEMWat SS18
[6:5:6:5] – NP
Baseline separation
10
NN R2
O
R1
O
Three chemistry steps performed without purification to give
intermediate of purity 64%
200 mg  HEMWat SS19
[3:2:3:2] – NP
Product purity 98%
separation
scaled-up to
Spectrum
semi-prep column.
1.8 g injection gave
50%, w/w recovery,
equivalent to
approximately 80%
recovery based on
purity
11  API + excess reagent + by-product Partial
separation
Hexane:EtOAc:MeOH:
water:THF containing
1% NH4OH [2:2:2:2:1]
Excess reagent
separated.
By-product not
separated
12 Mother liquors containing 7%, w/w  API 200 mg HEMWat  SS17.5
[12:11:12:11] – NP
Product purity
96.4%
Table 4
Details of example applications involving removal of impurities used for HPCCC assessment.
Example Mixture Loading (mg) Solvent system Result
13 Reaction intermediate containing 20% of an unexpected
process related impurity
290 HEMWat 23
[4:1:4:1] – NP
Crude purity of target 73%
by peak area. Final product
purity >98% in 30 min with
95% recovery. Predicted
throughput on mid  system
60 g/h
14  Synthetic Metabolite (87%) containing multiple impurities
including critical bromo impurity
200 HEMWat14
[1:2:1:2] – NP
Product isolated in 96.5%
purity and containing
<0.5% of bromo impurity
15
N R2
R1
N R2
450 HEMWat SS17 Product contains <1%
o
p
5
u
i
i
i
a
T
u
t
v
unwanted isomer (<0.1%). The mass balance gives a 120 mg recov-
ery of the target compound from a total of 260 mg crude injected.
The peaks eluting before 1.5 min  were not taken into considerationN
O
N
R1O
n a HEMWat #11 (1:4:1:4) phase system [9] operating in reversed
hase mode with an additive of 0.1% HCl.
.1.3. Loading studies and scale up
Loading studies were ﬁrst performed on the DE Mini (18 ml  col-
mn, 0.8 mm bore) with a ﬂow rate of 1 ml/min at 2100 rpm with an
nitial sample loading of 4 mg  in 0.1 ml  (Fig. 1a). Loading was  then
ncreased to 20 mg  in 0.5 ml  (not shown) to 50 mg  in 0.5 ml  loaded
n a 1:1 mix  of mobile and stationary phases (Fig. 1b). Fractions
fter 28 min  in Fig. 1b contained <0.5% of the unwanted isomer.
he process was then scaled up to the DE Spectrum (134 ml  col-
mn, 1.6 mm bore). As the length of the Spectrum column is almost
wice that of the Mini, volumetric scale up (ratio of the column
olumes – 7.4×)  could not be applied and linear scale up (4×)[1:1:1:1] – NP unwanted isomer and
impurities removed
would be conservative.1 In this case ﬂow rate was  scaled up lin-
early (4 ml/min) and sample loading somewhere between the two
at 5.2× to 260 mg  in 3 ml.  The result is shown in Fig. 1c where it can
be seen that the separation is longer, due to the longer column but
the resolution better. The HPLC analysis is shown in Fig. 2 for (a) the
starting material; (b) fractions from 8 to 42 min; (c) fractions from
43 to 62 min  and ﬁnally (d) fractions from 63 to 78 min. The frac-
tion in Fig. 2c gave a purity of 96.8% with no detectable amount of1 Volumetric scale up uses the ratio of the column capacities; linear scale up uses
the  ratio of the cross-sectional areas [9].
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Fig. 1. HPCCC loading and scale-up study using the analytical column of the DE Mini instrument for sample from application 2 in Table 1 for loadings of (a) 4 mg  and (b) 50 mg.
Analytical HPCCC run conditions: column: 18 ml,  0.8 mm bore; solvent system: hexane:ethyl acetate:methanol:water with 0.1% HCl (HEMWat – SS11) [1:4:1:4]. Operational
m , isocr
t g mo
b usion;
s
t
5
5
s
T
tode:  reversed phase (RP); ﬂow, 1 ml/min; rotation, 2100 rpm; temperature, 30 ◦C
o  the DE Spectrum instrument using the same sample, phase system and operatin
ore;  ﬂow, 4 ml/min; rotation, 1600 rpm; temperature, 30 ◦C, isocratic, elution extr
ince they are solvent systems peaks, which is why  the height of
hese peaks remains the same on all HPLC chromatograms.
.2. Case Study 2: separation of polar compounds
.2.1. Separation
Application 7 from Table 2 is a sample containing a bis-sodium
alt of an API (target) and two unknown impurities at 0.8% and 1.5%.
he aim was to isolate the API and reduce these impurities to less
han 0.1%. Fig. 3a shows the starting material (Rt = 1.96 min) withatic, elution extrusion; sample concentration 40 mg/ml. Semi-preparative scale up
de for a loading of (c) 260 mg. Semi-prep run conditions: column: 134 ml, 1.6 mm
 sample concentration 100 mg/ml.
impurities at 1.84 min  (1.5%) and 2.07 min  (0.76%). The 2.22 peak is
a degradant which forms during the HPLC process.
5.2.2. Solvent system selection
Several solvent systems were tried to get the partition
coefﬁcient in the appropriate range (0.5 < KD < 2.0). The sample par-
titioned into the lower phase (LP) for HEMWat phase systems 17, 14
and 10, therefore the target was highly polar. As samples dissolved
well in mixtures containing DCM and MeCN, polar phase systems
using these solvents were tried. The DCM phase systems tended
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F g mate
f .6 mm
1
t
w
n
ﬁ
K
5
p
p
D
0
(
8
2ig. 2. HPLC analysis for Case Study 1, application 2 in Table 1 for (a) crude startin
ractions from 63 to 78 min. A Gemini NX, 3 , C18 column was  used 110 A˚ (50 × 4
 min  then 2 min  equilibration at 5%B. Flow rate: 1 ml/min; detection 220 nm.
o emulsify, but the MeCN systems with the addition of salt [10]
ere successful with the ﬁnal optimised solvent system chosen as
-BuOH:MeCN:1 M aq. NaOAc (4:1:5) giving a target partition coef-
cient of KD = 1.6 (Rt = 1.96 – Fig. 3a) with impurities partitioning at
D = 1.23 (Rt = 2.22) and KD = 2.42 (Rt = 1.84).
.2.3. The HPCCC separation
The chromatogram for a 27 mg  injection of crude (55%, w/w
urity (15 mg)  of target compound) in 1 ml  of stationary (lower)
hase is shown in Fig. 4 with the following run conditions: Column:
ynamic Extractions Midi HPCCC analytical column/coil (22.5 ml,
.8 mm bore); ﬂow rate: 0.5 ml/min; rotational speed: 1400 rpm
240 g); temperature: 30 ◦C; stationary phase volume retention (Sf):
2%.
In Fig. 4, the 2.07 min  impurity elutes in fractions 1–5 between
6 and 45 min. The desired product elutes next between 70 andrial, (b) fractions from 2 to 42 min, (c) fractions from 43 to 62 min  (target) and (d)
).  Mobile phase A – 0.1% aq. TFA, B – MeCN; Method: 5–25%B over 5 min, 90%B for
90 min  which approximately matches the predicted retention time
calculated from the partition study results. The 1.84 min  impurity is
retained in the stationary phase. Fig. 3b is the HPLC chromatogram
of fraction 13 (between 74 and 76 min). Fractions 10–20 present a
similar purity proﬁle. The impurity at 2.22 is a degradation product
of the main peak under HPLC conditions.
5.3. Case Study 3: separation of crude mixtures
5.3.1. Separation
The aim was to separate a monohydroxy compound from an
approximately 2:5:1 mixture (see HPLC chromatogram of the crude
– Fig. 5) of dihydroxy, monohydroxy and dimethoxy compounds
illustrated in Table 3, application 9.
Test tube partitioning studies for 5 different HEMWat phase
systems (Fig. 6) showed that HEMWat #18 (heptane:ethyl
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Fig. 3. HPLC chromatogram of (a) starting material for Case Study 2 (application 7,
Table 2) with target at 97.07% purity (1.96 min) and impurities at 1.53% (1.84 min),
0.76% (2.07 min) and 0.65% (2.24) and (b) HPLC chromatogram of fraction 13 show-
ing 99.48% pure target material. An Agilent Zorbax SB-C18, 1.8  column was used
(50 × 3.0 mm).  Mobile phase A – 0.5%, v/v triﬂuoroacetic acid in water. Mobile phase
B  – 0.05%, v/v triﬂuoroacetic acid in acetonitrile; method: 0–95%B over 2.5 min, 95%B
for  0.2 min  then 1.3 min  equilibration at 0%B. Flow rate: 1.5 ml/min.
Fig. 5. HPLC chromatogram of starting material for Case Study 3 showing an approx-
imate 2:5:1 ratio between the dihydroxy, monohydroxy and dimethoxy compounds
illustrated in Table 3, application 9. A Waters Symmetry C18, 3.5  column was
Fig. 4. HPCCC chromatogram for Case Study 2 using the analytical column of the DE Midi i
22.5  ml,  0.8 mm bore; solvent system: n-BuOH:MeCN:1 M aq. NaOAc [4:1:5]; stationary
(0.5  ml/min), rotation (1400 rpm); temperature (30 ◦C), isocratic, elution extrusion; sampused (75 × 4.6 mm)  at 30 ◦C. Mobile phase A – 0.05%, v/v triﬂuoroacetic acid in
water. Mobile phase B – acetonitrile. Method: 50–90%B over 10 min, then 4 min
equilibration at 50%B. Flow rate: 1.0 ml/min.
acetate:methanol:water – 6:5:6:5) gave partition coefﬁcients in the
appropriate range for CCC (KD = 0.5–2.0, Log10 (KD) = −0.3 to +0.3).
A DE Midi analytical column (25 ml,  0.8 mm bore) was  used for
the sample loading studies. Fig. 7a shows that the main compo-
nents are well separated with contaminant 2 eluting ﬁrst, the target
compound second and contaminant 1 eluting third.5.3.2. Sample loading
The effect of increasing sample loading is shown in Fig. 7a–c
for 10.9 mg  (a), 55 mg  (b) and 220 mg  (c). The ﬁrst chromatogram
nstrument for sample from application 7 in Table 2. HPCCC run conditions: column:
 phase retention (Sf): 82%; operational mode: normal phase (NP); method: ﬂow
le loading 27 mg  of crude in 1 ml of stationary (lower) phase.
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Fig. 7. HPCCC loading study for Case Study 3 using the analytical column of the DE
Midi instrument for sample from application 9 in Table 3 (a) 10.9 mg,  (b) 55 mg and
(c)  220 mg.  HPCCC run conditions: column: 25 ml, 0.8 mm bore; solvent system: hex-
ane:ethyl acetate:methanol:water (HEMWat – SS18) [6:5:6:5]. Operational mode:
normal phase (NP); method: ﬂow (2 ml/min to 32 min then 4 ml/min), rotation
(1400 rpm); temperature (30 ◦C), isocratic, elution extrusion; sample concentration10
ound and 2 impurities for application 9 in Table 3. HEMWat phase system 18
6:5:6:5) was chosen for the HPCCC runs of Fig. 7.
Fig. 7a) shows that all three compounds can be eluted, but as impu-
ity 1 is so well retained in the lower phase the ﬂow was doubled to
 ml/min to elute it earlier. Increasing the loading to 55 mg  broad-
ned the target peak considerably showing that the run could be
topped after 30 min  with impurity 1 still in the column (Rs12 = 2.3
ompared to 3.1 at 10.9 mg  loading). This could then be quickly
ushed out as fresh stationary phase was used to ﬁll the column
or a total cycle time of 45 min. Purities in these ﬁrst two  load-
ngs was ∼100%, but when loading was increased to 220 mg  in
 ml  with some MeOH added to help solubility – the purity of the
arget peak reduced to 85% (Rs12 = 1.3 compared to 2.3 for 55 mg
oading).
.3.3. Projected further scale up and cost comparisons
With a total cycle time of 45 min  including reﬁlling with fresh
tationary phase and a sample loading of 110 mg  (i.e. between those
llustrated in Fig. 7b and c where resolution Rs was  interpolated to
e approximated 1.9) it would be possible to get a throughput of
tarting material of 24.4 g/h leading to a recovery of 15.3 g/h target
ompound. This can be volumetrically scaled up [11] as shown in
able 5. In a pilot plant environment the Maxi would enable puriﬁ-
ation of 2.6 kg/day. Note that this is much less than Case Study 4
Section 5.4) where solubility was much better and assumes the
evelopment of a pilot scale Maxi operating at 240 g for 24 h/day.
A material cost comparison for the puriﬁcation of 16 kg of the
arget compound is given in Table 6. The solid phase chromatog-
aphy used 16 runs loading 1 kg on a 20 kg silica gel cartridge
olumn. The dihydroxy impurity was very strongly retained on the
ilica gel and therefore a new cartridge was used for each puriﬁca-
ion resulting in a high cost for stationary phase which would be
voided using HPCCC. In this case HPCCC uses 20% less solvent and
s only 15% of the cost of silica gel chromatography. Note that only
olvent and stationary phase costs have been taken into account.
able 5
he estimated throughput for analytical, preparative and pilot scale HPCCC instru-
ents for application 9, Table 3.
Instrument Column volume Throughput Throughput (g/week)
Midi 25 ml  0.15 g/h 4.6a
Midi 980 ml  6 g/h 180a
Maxi 4.6 L 28 g/h 0.7b
Maxi 18 L 110/h 2.6b
a Assumes lab instrument runs for 30 h/week.
b Assumes 240 g instrument in pilot plant and 24 h operation.43  mg/ml. All sample loaded in stationary phase with a small amount of MeOH to
aid  solubility.
Equipment costs, disposal costs, workforce costs, overheads, energy
and environmental costs have not been included.
5.4. Case Study 4: removal of impurities
5.4.1. Separation
Application 15 from Table 4 is an intermediate puriﬁcation of
a crude sample containing a pair of regio-isomers in the approxi-
mate ratio 5:1 of the required to the unwanted isomer. The material
has previously been separated by silica gel chromatography with
40 kg processed in 8 runs on 20 kg columns with the unusually high
loading of 25%, w/w.  Could CCC match this performance? There was
58% of the target isomer in the crude (Fig. 8a) and the aim was  to
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Table 6
The material costs comparison of MPLC vs. HPCCC for application 9, Table 3.
Input material Cost/L or kg (unspeciﬁed units) Silica chromatography CCC
Volume (weight) Cost (units) Volume (L) Cost (units)
Heptane 4 12,000 L 48,000 3300 13,000
Ethyl  acetate 1 3000 L 3000 2700 2700
Methanol 0.4 0 L – 3300 1300
Water 0 0 L – 2700 0
,000 L
0 kg 
a
t
5
a
r
u
u
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i
f
m
l
a
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u
o
c
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r
eTotal  organic solvent – 15
Solid  stationary phase 190 32
Materials cost (units) – 
chieve a purity for the target compound of >98% purity or <2% of
he unwanted isomer and impurities.
.4.2. Loading studies and scale-up to semi-prep
After initial partition studies it was found that hexane:ethyl
cetate:methnol:water (HEMWat #18) [1:1:1:1] gave distribution
atios (KD) of 0.71 and 1.41 in normal phase for the target and
nwanted isomer with an  ˛ of 2. Loading studies were performed
sing the DE Spectrum (Dynamic Extractions Ltd., 890 Plymouth
oad, Slough, UK) instrument with its analytical coil (23 ml)  operat-
ng at 1 ml/min, 1600 rpm and 30 ◦C. The results are shown in Fig. 9
or (a) 100 mg,  (b) 200 mg  and (c) 450 mg  sample loading in the
obile phase operating in normal phase mode. It can be seen that
oading can be increased to 450 mg  and that 98.8% purity (Fig. 8b
nd inset in Fig. 9c) is achieved with a yield of 95% from fractions
0 to 27 in Fig. 9c.
This was then scaled up to the DE Spectrum semi-prep col-
mn  (134 ml)  on the same instrument with the same phase system
perating at 6 ml/min, 1600 rpm and 30 ◦C in normal phase in iso-
ratic elution–extrusion mode. Initially volumetric scale up was
ig. 8. HPLC traces of sample from Case Study 4, application 15 in Table 4 (a) crude with 58
un  (Fig. 9c). HPLC conditions: Gemini NX, 5 m,  C18, 110 A˚ (150 × 4.6 mm);  mobile pha
quilibration at 5%B; ﬂow rate: 1 ml/min; detection: 220 nm. 51,000 12,000 17,000
61,000 0 0
112,000 17,000
used with a loading of 2.6 g in 18 ml,  but it was  found that even
higher loading was possible (4 g in 26 ml  – Fig. 10)  achieving a
purity of 98.6% with 87% recovery therefore giving greater overall
throughput at acceptable yield.
5.4.3. Projected further scale up and cost comparisons
With a run time of about 28 min  and allowing a further 20 min
for extrusion and reﬁlling – a cycle time of 48 min  is feasible leading
to a throughput of 5 g/h. This can be volumetrically scaled up [11]
as shown in Table 7. In a pilot plant environment the Maxi would
enable puriﬁcation of 40 kg of material in <1 week once the 240 g
version of Maxi has been constructed – a follow-on development
resulting from the TSB-STEP research programme. This will then be
a realistic alternative to conventional chromatography.
A material cost comparison for the puriﬁcation of 1 kg of inter-
mediate sample is given in Table 8. In this case CCC is competitive
with silica gel chromatography, with CCC using 10% less solvent
and only being 16% of the cost of silica gel chromatography. Note
that only solvent and stationary phase costs have been taken into
% target present and (b) fractions 20–27 puriﬁed to 98.8% from Spectrum semi-prep
se A = water + 0.1% TFA, B = MeCN + 0.1% TFA; method: 5–95%B over 10 min, 5 min
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Fig. 9. HPCCC loading study using the analytical column of the DE Spectrum instrument for sample from application 15 in Table 4 (a) 100 mg, (b) 200 mg and (c) 450 mg
with  HPLC trace from Fig. 8b inset. HPCCC run conditions: column: 23 ml,  0.8 mm bore; solvent system: hexane:ethyl acetate:methanol:water (HEMWat – SS17) [1:1:1:1];
stationary phase retention (Sf): 79%; operational mode: normal phase (NP); method: ﬂow (1 ml/min), rotation (1600 rpm); temperature (30 ◦C), isocratic, elution extrusion;
sample loading (a) 100 mg in 1 ml;  (b) 200 mg  in 2 ml  and (c) 450 ml in 4 ml.  All sample loaded in mobile phase dissolving the sample in the following order: EtOAc (34%) and
then  MeOH (2.5%) before slow addition of hexane.
Table 7
The estimated throughput for semi-preparative, preparative and pilot scale HPCCC instruments for application 15, Table 4.
Instrument Column volume Throughput Throughput
Spectrum 134 ml  5 g/h 150 g/weeka
Midi 980 ml 37 g/h 1.1 kg/weeka
Maxi 4.6 L 175 g/h 4.2 kg/weekb
Maxi 18 L 685/h 16.4 kg/weekb
a Assumes lab instrument runs for 30 h/week.
b Assumes 240 g instrument in pilot plant and 24 h operation.
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Table 8
The material costs comparison of MPLC vs. HPCCC for application 15, Table 4.
Input Material Cost/L or kg (unspeciﬁed units) Silica chromatography CCC
Volume (weight) Cost (units) Volume (L) Cost (units)
Heptane 4 76 L 304 34 136
Ethyl  acetate 1 19 L 19 28 28
Methanol 0.4 0 L – 23 9
Water 0 0 L – 22 0
Total  organic solvent – 95 L 
Solid  stationary phase 185 4 kg 
Materials cost (units) – 
Fig. 10. Representation of HPCCC chromatogram for Case Study 4 indicating target
compound and impurities for the scale-up to the DE Spectrum semi-prep col-
umn.  Run conditions: column: 134 ml,  1.6 mm bore; solvent system: hexane:ethyl
acetate:methanol:water (HEMWat – SS17) [1:1:1:1]. Operational mode: normal
phase (NP); method: ﬂow (6 ml/min), rotation (1600 rpm); temperature (30 ◦C), iso-
c
p
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c
o
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t
l
t
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e
fratic, elution extrusion; sample loading, 4 g in 26 ml.  Recovery, 87%. Same sample
reparation strategy as for analytical runs.
ccount. Equipment costs, overheads, energy and environmental
osts have not been included.
. Conclusions
The TSB-STEP research programme described in this paper has
roved to be a very successful teaming involving end users, sup-
ly companies and academics. What started as a phased study
nvolving analytical, preparative and process scale objectives soon
hanged to become theme driven user led research programme
ocussing on product integration and automation, generating a
omprehensive applications portfolio, new solvent system devel-
pment, improving instrument reliability, continuous processing
nd scale up and demonstrating value. This paper has focussed on
he “generating a comprehensive applications portfolio” theme. It
ists 15 of the 30+ applications studied in the research programme
hat can be put in the public domain. These have been categorised
nto isomer separations, polar separations, separations from crude
xtracts and removal of impurities. Case studies have been taken
rom each of these categories and, where scale up was  projected, it
[
[323 85 173
740 0 0
1063 173
was  demonstrated that in speciﬁc cases HPCCC would use between
10% and 20% less solvent. In particular, due to the elimination of
the cost of silica based stationary phase required for conventional
chromatography, the use of HPCCC was projected to lead to sig-
niﬁcant cost savings at scale. 85% of the applications undertaken
by the consortium were successful and, of the ones that were not,
only one failed completely and the rest were partially successful.
This research has shown that the high performance countercurrent
chromatography instruments now being developed are capable of
becoming a valuable platform technological resource for the phar-
maceutical industry offering for some applications a step-change
reduction in costs.
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